Approval Year
| Substance Class |
Concept
|
| Record UNII |
4A6ZWS8R8E
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
880922
Created by
admin on Sat Dec 16 19:13:35 GMT 2023 , Edited by admin on Sat Dec 16 19:13:35 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
4A6ZWS8R8E
Created by
admin on Sat Dec 16 19:13:35 GMT 2023 , Edited by admin on Sat Dec 16 19:13:35 GMT 2023
|
PRIMARY |
This is a non-substance concept
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
|
||
|
|
TARGET->LIGAND |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
A bispecific antibody with dual functions of targeting DLL3-expressing cancer cells and blocking the CD47 “don’t eat me” signal on the same cancer cells is expected to activate the macrophages of innate immunity to specifically kill cancer cells that express both DLL3
and CD47
|
This is a non-substance concept